KLERTIS

This brand name is authorized in Lithuania, Poland, Romania.

Active ingredients

The drug KLERTIS contains one active pharmaceutical ingredient (API):

1
UNII V99T50803M - SUNITINIB
 

Sunitinib inhibits multiple RTKs that are implicated in tumour growth, neoangiogenesis, and metastatic progression of cancer.
 
Read more about Sunitinib

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L01EX01 Sunitinib L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
LT Valstybinė vaistų kontrolės tarnyba 1092557, 1092558, 1092559, 1092560, 1092561, 1092562
PL Rejestru Produktów Leczniczych 100430074, 100430080, 100430097
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W68008001, W68008002, W68009001, W68009002, W68010001, W68010002

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈